Literature DB >> 16021575

Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.

Daniela Massi1, Antonella Naldini, Camilla Ardinghi, Fabio Carraro, Alessandro Franchi, Milena Paglierani, Francesca Tarantini, Sheyda Ketabchi, Giuseppe Cirino, Morley D Hollenberg, Pierangelo Geppetti, Marco Santucci.   

Abstract

Protease-activated receptors (PARs) are members of the G protein-coupled receptor superfamily that are activated by the proteolytic cleavage of their amino terminal domain. PAR-1 activation by thrombin results in several biologic effects, including platelet adhesion to other cells or extracellular matrix, fibroblast, and endothelial cell growth, whereas PAR-2, activated by trypsin, has mainly a proinflammmatory and angiogenetic role. PAR-1 and PAR-2 modulate cell proliferation in physiopathologic cell invasion processes, suggesting that they may play a role in the setting of cancer growth and metastasis. Here, we have investigated the expression of PAR-1 and PAR-2 proteins by immunohistochemistry in a series of benign and malignant melanocytic lesions: 20 melanocytic lesions (10 common melanocytic nevi and 10 atypical or "dysplastic" melanocytic nevi) and 50 melanomas (10 in situ melanomas, 10 melanomas T1, 10 melanomas T2, 10 melanomas T3 to T4, and 10 metastatic melanomas). PAR-1 was significantly overexpressed in atypical nevi and melanomas in comparison with common melanocytic nevi. PAR-2 was strongly and diffusely expressed by immunohistochemistry in all melanocytic lesions, with no statistically significant differences between nevi and melanomas. Because we found a differential expression in PAR-1 protein, but not in PAR-2, we next investigated the expression of PAR-1 messenger RNA (mRNA) by ribonuclease protection assay in paraffin-embedded tissues using a paraffin block RNA isolation procedure. Similarly to immunohistochemical results, PAR-1 mRNA expression was significantly higher in atypical nevi and melanomas in comparison with common nevi and controls. Overexpression of PAR-1 in atypical nevi and melanomas supports a role for PAR-1 in the initial phases of melanoma development as well as in tumor progression and metastasis. Conversely, the significance of PAR-2 up-regulation in both benign and malignant melanocytic lesions requires further research.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16021575     DOI: 10.1016/j.humpath.2005.04.008

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  33 in total

1.  Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype.

Authors:  Gabriel J Villares; Maya Zigler; Andrey S Dobroff; Hua Wang; Renduo Song; Vladislava O Melnikova; Li Huang; Russell R Braeuer; Menashe Bar-Eli
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

Review 2.  PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis.

Authors:  Maya Zigler; Takafumi Kamiya; Emily C Brantley; Gabriel J Villares; Menashe Bar-Eli
Journal:  Cancer Res       Date:  2011-10-18       Impact factor: 12.701

3.  Use of Nanoparticles in Delivery of Nucleic Acids for Melanoma Treatment.

Authors:  Mohammad A Obeid; Alaa A A Aljabali; Meriem Rezigue; Haneen Amawi; Hanin Alyamani; Shatha N Abdeljaber; Valerie A Ferro
Journal:  Methods Mol Biol       Date:  2021

4.  Proteinase-activated receptor 2 promotes cancer cell migration through RNA methylation-mediated repression of miR-125b.

Authors:  Lan Yang; Yiming Ma; Wenxiao Han; Weiwei Li; Liang Cui; Xinhua Zhao; Yantao Tian; Zhixiang Zhou; Wengong Wang; Hongying Wang
Journal:  J Biol Chem       Date:  2015-09-09       Impact factor: 5.157

Review 5.  Expression of proteinase-activated receptor 1-4 (PAR 1-4) in human cancer.

Authors:  Andrea Pia Elste; Iver Petersen
Journal:  J Mol Histol       Date:  2010-06-20       Impact factor: 2.611

6.  Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype.

Authors:  Antonietta Silini; Carmen Ghilardi; Camilla Ardinghi; Sergio Bernasconi; Paolo Oliva; Fabio Carraro; Antonella Naldini; Maria Rosa Bani; Raffaella Giavazzi
Journal:  Clin Exp Metastasis       Date:  2009-12-20       Impact factor: 5.150

7.  PAR1 inhibition suppresses the self-renewal and growth of A2B5-defined glioma progenitor cells and their derived gliomas in vivo.

Authors:  R Auvergne; C Wu; A Connell; S Au; A Cornwell; M Osipovitch; A Benraiss; S Dangelmajer; H Guerrero-Cazares; A Quinones-Hinojosa; S A Goldman
Journal:  Oncogene       Date:  2015-11-30       Impact factor: 9.867

Review 8.  G-protein-coupled receptors and melanoma.

Authors:  Hwa Jin Lee; Brian Wall; Suzie Chen
Journal:  Pigment Cell Melanoma Res       Date:  2008-05-27       Impact factor: 4.693

9.  A matrix metalloproteinase-1/protease activated receptor-1 signaling axis promotes melanoma invasion and metastasis.

Authors:  J S Blackburn; I Liu; C I Coon; C E Brinckerhoff
Journal:  Oncogene       Date:  2009-09-07       Impact factor: 9.867

10.  Emerging roles of PAR-1 and PAFR in melanoma metastasis.

Authors:  Vladislava O Melnikova; Gabriel J Villares; Menashe Bar-Eli
Journal:  Cancer Microenviron       Date:  2008-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.